A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The adverse metabolic consequences of obesity are best predicted by the quantity of visceral fat. Excess glucocorticoids produce visceral obesity and diabetes, but circulating glucocorticoid levels are normal in typical obesity. Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11β hydroxysteroid dehydrogenase type 1 (11β HSD-1). We created transgenic mice overexpressing 11β HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans. These mice had increased adipose levels of corticosterone and developed visceral obesity that was exaggerated by a high-fat diet. The mice also exhibited pronounced insulin-resistant diabetes, hyperlipidemia, and, surprisingly, hyperphagia despite hyperleptinemia. Increased adipocyte 11β HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“other health outcomes associated with better quality of life improved, including sleep apnoea136 and mobility137.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [137]
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26746 · Cited by 3,237
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Self-citationSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citationThe Degree of Masculine Differentiation of Obesities
VAGUE, J. (1956) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/4.1.20 · Cited by 1,410
Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
Abel, E. D., Peroni, O., Kim, J. K., Kim, Y.-B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., & Kahn, B. B. (2001) · Nature · doi:10.1038/35055575 · Cited by 1,253
Frühbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e827 · Cited by 974
Research works printed but not linked: 5
- 10.1210/jcem.86.3.7453 · doi:10.1210/jcem.86.3.7453 · Paper page
- 10.1101/gad.7.7b.1318 · doi:10.1101/gad.7.7b.1318 · Paper page
- Supplementary data are available on Science Online at www.sciencemag.org/cgi/content/full/294/5549/2166/DC1.
- Strack A. M., Bradbury M. J., Dallman M. F., Am. J. Physiol. 268, R183 (1995).
- 10.1210/jcem.83.5.4951 · doi:10.1210/jcem.83.5.4951 · Paper page
Cited by
Items 801–900 of 1,003
Rosiglitazone decreases 11β‐hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue
Mai, K., Andres, J., Bobbert, T., Maser‐Gluth, C., Möhlig, M., Bähr, V., Pfeiffer, A. F. H., Spranger, J., & Diederich, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02903.x · Cited by 36
11β‐Hydroxysteroid Dehydrogenase Type 1 in Obesity
Walker, B. R. (2004) · Obesity Research · doi:10.1038/oby.2004.1 · Cited by 36
Torrecilla, E., Fernández‐Vázquez, G., Vicent, D., Sánchez‐Franco, F., Barabash, A., Cabrerizo, L., Sánchez-Pernaute, A., Torres, A. J., & Rubio, M. Á. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0524-9 · Cited by 35
Stewart, P. M. (2005) · Clinical Medicine · doi:10.7861/clinmedicine.5-2-142 · Cited by 35
A glucocorticoid- and diet-responsive pathway toggles adipocyte precursor cell activity in vivo
Wong, J. C., Krueger, K. C., Costa, M. J. D. C., Aggarwal, A., Du, H., McLaughlin, T., & Feldman, B. J. (2016) · Science Signaling · doi:10.1126/scisignal.aag0487 · Cited by 35
Effect of Curcumin on Anthropometric Measures: A Systematic Review on Randomized Clinical Trials
Hariri, M., & Haghighatdoost, F. (2018) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1392263 · Cited by 35
“In murine models, overexpression of the 11bHSD1 gene increases cortisol levels by changing inactive cortisol into the active form [11] in adipose tissue, which causes central obesity and insulin resistance [12].”
BackgroundObesity and the developmental origins of health and disease
Kemp, M. W., Kallapur, S. G., Jobe, A. H., & Newnham, J. P. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2010.01940.x · Cited by 35
Takaya, J., Iharada, A., Okihana, H., & Kaneko, K. (2013) · Nutrition Research · doi:10.1016/j.nutres.2013.07.015 · Cited by 35
“[24] Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al.”
BackgroundAoyagi, A., Ito‐Kobayashi, M., Ono, Y., Furukawa, Y., Takahashi, M., Muramatsu, Y., Umetani, M., & Takatsu, T. (2008) · The Journal of Antibiotics · doi:10.1038/ja.2008.122 · Cited by 35
“As glucocorticoids oppose the insulin effect, several studies on mice lacking [1] or overexpressing [2] 11b -HSD1 reported that 11b HSD1 plays an important role in Type 2 diabetes and metabolic syndrome.”
BackgroundVogel, H., Scherneck, S., Kanzleiter, T., Benz, V., Kluge, R., Stadion, M., Kryvych, S., Blüher, M., Klöting, N., Joost, H., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds213 · Cited by 35
Harno, E., Cottrell, E. C., Yu, A., deSchoolmeester, J., Gutierrez, P. M., Denn, M., Swales, J. G., Goldberg, F. W., Bohlooly‐Y, M., Andersén, H., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1613 · Cited by 35
Champagne, C. D., Tift, M. S., Houser, D. S., & Crocker, D. E. (2015) · Conservation Physiology · doi:10.1093/conphys/cov004 · Cited by 35
“Adipose tissue contains high levels of the activating dehydrogenase that can lead to substantially higher concentrations of GCs at target tissues than those present in the circulation (Masuzaki et al., 2001).”
BackgroundLutz, S. Z., Peter, A., Machicao, F., Lamprinou, A., Machann, J., Schick, F., Königsrainer, I., Königsrainer, A., Fritsche, A., Staiger, H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2498 · Cited by 27
Molecular Screening of the 11β‐HSD1 Gene in Men Characterized by the Metabolic Syndrome
Robitaille, J., Brouillette, C., Houde, A., Després, J., Tchernof, A., & Vohl, M. (2004) · Obesity Research · doi:10.1038/oby.2004.196 · Cited by 35
“Moreover, transgenic mice overexpressing 11 -HSD1 in adipose tissue developed visceral obesity and an insulin-resistant state and hyperlipidemia, leading the investigators to suggest that 11 -HSD1 may be a common molecular etiology for visceral obesity and the metabolic syndrome (5).”
BackgroundXiang, J. S., Wan, Z., Li, H., Ipek, M., Binnun, E., Nunez, J., Chen, L.-R., McKew, J. C., Mansour, T. S., Xu, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8004948 · Cited by 35
Baker, M. E. (2010) · Nature Precedings · doi:10.1016/j.febslet.2010.03.036 · Cited by 35
“Over-expression of 11 -HSD1 in fat cells leads to metabolic syndrome [18-20].”
BackgroundSubramanian, S., DeRosa, M. A., Bernal-Mizrachi, C., Laffely, N., Cade, W. T., Yarasheski, K. E., Cryer, P. E., & Semenkovich, C. F. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00230.2006 · Cited by 34
“Excessive tissue generation of active glucocorticoids by overexpression of 11 -hydroxysteroid dehydrogenase type 1(11 -HSD1) increases (19), and interference with this process decreases (14), insulin resistance.”
BackgroundEndocrine consequences of childhood obesity: a narrative review
Badr, M., El-Rabaa, G., FREIHA, M., Kędzia, A. W., & Niechciał, E. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1584861 · Cited by 34
Hamilton, B. S., Himmelsbach, F., Nar, H., Schuler‐Metz, A., Krosky, P. M., Guo, J., Guo, R., Meng, S., Zhao, Y., Lala, D. S., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.053 · Cited by 34
Even, S., Dulak-Lis, M. G., Touyz, R. M., & Cat, A. N. D. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0013 · Cited by 34
Rossi, A., Simeoli, C., Salerno, M., Ferrigno, R., Casa, R. D., Colao, A. A. L., Strisciuglio, P., Parenti, G., Pivonello, R., & Melis, D. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01377-w · Cited by 34
Takeshita, Y., Watanabe, S., Hattori, T., Nagasawa, K., Matsuura, N., Takahashi, K., Murohara, T., & Nagata, K. (2015) · Hypertension Research · doi:10.1038/hr.2015.77 · Cited by 34
Feed-Forward Inhibition of Androgen Receptor Activity by Glucocorticoid Action in Human Adipocytes
Hartig, S. M., He, B., Newberg, J. Y., Ochsner, S. A., Loose, D. S., Lanz, R. B., McKenna, N. J., Buehrer, B. M., McGuire, S. E., Marcelli, M., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.020 · Cited by 34
“Indeed, further supporting inhibition of AR transcriptional activity during fat maturation, each MIX component has been shown to induce adipogenesis in vivo (De Vos et al., 1996; Fujikura et al., 2005; Madsen et al., 2008; Masuzaki et al., 2001; Masuzaki et al., 2003).”
BackgroundCellular heterogeneity in superficial and deep subcutaneous adipose tissues in overweight patients
Boulet, N., Estève, D., Bouloumié, A., & Galitzky, J. (2012) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-012-0225-4 · Cited by 34
“Depending on the location, its excessive development is differentially associated with metabolic and cardiovascular risk, increased visceral AT (VAT) mass being considered as the most deleterious location [2, 19].”
Backgrounddo Nascimento, F. V., Piccoli, V., Beer, M. A., von Frankenberg, A. D., Crispim, D., & Gerchman, F. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0036-1 · Cited by 34
“Overexpression of the HSD11B1 gene in adipocytes has been shown to be related to high cortisol concentrations in adipose tissue and to the development of central obesity, insulin resistance (IR), and diabetes in mouse models [2].”
BackgroundJaimes, R., & Rocco, A. G. (2014) · BMC Anesthesiology · doi:10.1186/1471-2253-14-70 · Cited by 34
“The cortisol, thus produced, augments the cortisol from the adipose tissue, ultimately promoting the metabolic syndrome [14,15,20,32-34].”
BackgroundPetrus, P., Rosqvist, F., Edholm, D., Mejhert, N., Arner, P., Dahlman, I. A., Rydén, M., Sundbom, M., & Risérus, U. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0042-1 · Cited by 34
“display decreased VAT mass [9] whereas reciprocal effects are observed in mice over-expressing HSD11B1 [10].”
BackgroundNeonatal Exposure to Leptin Augments Diet‐induced Obesity in Leptin‐deficient Ob/Ob Mice
Yura, S., Itoh, H., Sagawa, N., Yamamoto, H., Masuzaki, H., Nakao, K., Kawamura, M., Mogami, H., Ogawa, Y., & Fujii, S. (2008) · Obesity · doi:10.1038/oby.2008.57 · Cited by 34
“It is often associated with insulin resistance, dyslipidemia, and hypertension; thus, the concept of the metabolic syndrome has been proposed (2,3).”
BackgroundSelf-citationInsulin Action on Expression of Novel Adipose Genes in Healthy and Type 2 Diabetic Subjects
Koistinen, H. A., Forsgren, M., Wallberg‐Henriksson, H., & Zierath, J. R. (2004) · Obesity Research · doi:10.1038/oby.2004.5 · Cited by 34
Kovačević, S., Brkljačić, J. M., Matić, G. M., & Elaković, I. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0644-1 · Cited by 33
“Transgenic mice overexpressing 11bHSD1 in the adipose tissue develop phenotype characteristics of metabolic syndrome, including central adiposity [16], while 11bHSD1 knockout mice are resilient to obesity and accompanying complications [19].”
BackgroundPaternain, L., García‐Díaz, D. F., Milagro, F. I., González‐Muniesa, P., Martínez, J. A., & Campión, J. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.01.017 · Cited by 33
“In striking contrast with Lep mice [80,85] and Zucker fa/ fa rats [47], high-fat-fed animals showed lower levels of 11β-HSD-1 and GR inWAT but higher in liver.”
Salehzadeh, F., Al‐Khalili, L., Kulkarni, S. S., Wang, M., Lönnqvist, F., & Krook, A. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.944 · Cited by 33
“Conversely, mice with a targeted adipocyte-specific HSD1 overexpression display insulin resistance, hyperglycemia, dyslipidemia and increased visceral adiposity [16].”
BackgroundSakamuri, S. S. V. P., Sukapaka, M., Prathipati, V. K., Nemani, H., Putcha, U. K., Pothana, S., Koppala, S. R., Ponday, L. R. K., Acharya, V., Giridharan, N. V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050216 · Cited by 33
“Circulatory TG, hepatic steatosis and gene expression 11b-HSD1 knock-out mice have lower plasma triglyceride levels, where as transgenic mice over-expressing 11b-HSD1 in adipose tissue or in liver have elevated plasma triglycerides [7,8].”
BackgroundInfluentialSvendsen, P. F., Madsbad, S., Nilas, L., Paulsen, S. K., & Pedersen, S. B. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.165 · Cited by 33
Veyrat‐Durebex, C., Deblon, N., Caillon, A., Andrew, R., Altirriba, J., Odermatt, A., & Rohner‐Jeanrenaud, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034002 · Cited by 33
“Strikingly, these rodents have developed a phenotype similar to the metabolic syndrome, with increased central adiposity, impaired glucose tolerance, hypertriglyceridemia but normal circulating corticosterone levels [19,20].”
BackgroundEspíndola-Antunes, D., & Kater, C. E. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800027 · Cited by 33
“Transgenic mice overexpressing 11βHSD1 in adipose tissue develop obesity and other features of the metabolic syndrome, presenting with elevated intra-adipose glucocorticoid concentrations and higher glucocorticoid receptor alpha (GRα) expression (24).”
BackgroundMiesel, A., Müller‐Fielitz, H., Jöhren, O., VOGT, F. M., & Raasch, W. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01726.x · Cited by 33
“, 1996) and obesity (Masuzaki et al., 2001).”
Synthesis of a Nonavalent Mannoside Glycodendrimer Based on Pentaerythritol
Al‐Mughaid, H., & Grindley, T. B. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo052045u · Cited by 33
Bates, H. E., Kiràly, M. A., Yue, J. T. Y., Montes, D. G., Elliott, M. E., Riddell, M. C., Matthews, S. G., & Vranić, M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.03.015 · Cited by 33
“HPA hyperactivity and altered glucocorticoid metabolism are associated with visceral adiposity, dyslipidemia, hyperglycemia, and insulin resistance [7,13-16].”
BackgroundTargher, G., Bertolini, L., Zoppini, G., Zenari, L., & Falezza, G. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01583.x · Cited by 33
Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes
Ahmed, I., Furlong, K., Flood, J. J., Treat, V., & Goldstein, B. J. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000212890.82339.8d · Cited by 33
“TZDs have been shown to improve this imbalanced release of cytokines resulting in enhanced glycemic control, increased hepatic and muscle insulin sensitivity, and improvement in b-cell function in both human(48) and animal models of type 2 diabetes.(49) Studies with TZDs have demonstrated a shift in the fat distributi…”
BackgroundLong, N. M., Smith, D. T., Ford, S. P., & Nathanielsz, P. W. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.05.051 · Cited by 32
Jiang, L., Qin, Y., Nong, J.-L., & An, H. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103143 · Cited by 32
Tarantino, G., Lobello, R., Scopacasa, F., Contaldo, F., Pasanisi, F., Cirillo, M., Caterina, M. D., Conca, P., Terracciano, D., Gennarelli, N., et al. (2007) · Clinical and investigative medicine · doi:10.25011/cim.v30i5.2895 · Cited by 32
Auvinen, H., Romijn, J. A., Biermasz, N. R., Havekes, L. M., Smit, J. W. A., Rensen, P. C. N., & Pereira, A. M. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1291305 · Cited by 32
“Second, patients with MetS show increased activity of the HPA-axis [ 9 ] , but the underlying mechanisms are only partially understood [ 10 ] .”
BackgroundInfluentialSchmidt, M. V., Schmidt, M. V., Czisch, M., Schmidt, M. V., Czisch, M., Sterlemann, V., Reinel, C., Sämann, P. G., & Müller, M. (2008) · Stress · doi:10.1080/10253890802049343 · Cited by 32
“As those mice also exhibited the pronounced insulinresistant diabetes and hyperlipidaemia among other symptoms, the authors proposed that increased adipocyte 11b HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome (Masuzaki et al. 2001).”
BackgroundArai, N., Masuzaki, H., Tanaka, T., Ishii, T., Yasue, S., Kobayashi, N., Tomita, T., Noguchi, M., Kusakabe, T., Fujikura, J., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0349 · Cited by 32
Self-citationZhu, L., Hou, M., Sun, B., Burén, J., Zhang, L., Yi, J., Hernell, O., & Li, X. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2708 · Cited by 32
Šimonytė, K., Olsson, T., Näslund, I., Angelhed, J., Lönn, L., Mattsson, C., & Rask, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2472 · Cited by 32
“Mice that selectively overexpressed 11 -HSD1 in AT exhibited central fat accumulation, hypertension, insulin resistance, increased levels of serum leptin, and reduced AT adiponectin mRNA expression (7).”
InfluentialLiu, Y. U., Park, F., Pietrusz, J. L., Jia, G., Singh, R. J., Netzel, B. C., & Liang, M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00067.2007 · Cited by 32
“Specific overexpression of 11 -HSD1 in visceral fat, but not in the liver, in mice causes central obesity (22, 33).”
BackgroundGambineri, A., Fanelli, F., Tomassoni, F., Munarini, A., Pagotto, U., Andrew, R., Walker, B. R., & Pasquali, R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1030 · Cited by 30
Sapouckey, S. A., Deng, G., Sigmund, C. D., & Grobe, J. L. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00087.2017 · Cited by 32
The cross talk of adrenal and Leydig cell steroids in Leydig cells
Wang, Y., Li, H., Zhu, Q., Li, X., Lin, Z., & Ge, R. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105386 · Cited by 32
Shah, I., Al-Dabbagh, B., Salem, A. E., Hamid, S. A. A., Muhammad, N., & Naughton, D. P. (2019) · BMC Chemistry · doi:10.1186/s13065-019-0627-2 · Cited by 32
Su, X., Vicker, N., Lawrence, H. R., Smith, A., Purohit, A., Reed, M. J., & Potter, B. V. L. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.03.019 · Cited by 32
Time of the day for 11β‐HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
Véniant, M. M., Hale, C., Komorowski, R., Chen, M. M., Jean, D. J. S., Fotsch, C. H., & Wang, M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00911.x · Cited by 32
Bauerle, K. T., & Harris, C. A. (2016) · Europe PMC (PubMed Central) · Cited by 31
The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease
Munteanu, C., & Schwartz, B. (2023) · Antioxidants · doi:10.3390/antiox12040903 · Cited by 30
Rhee, S. D., Kim, C.-H., Park, J. S., Jung, W. H., Park, S. B., Kim, H. Y., Bae, G. H., Kim, T. J., & Kim, K. Y. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.06.021 · Cited by 31
Gaware, R., Khunt, R. C., Czollner, L., Stanetty, C., Cunha, T. D., Kratschmar, D. V., Odermatt, A., Kosma, P., Jordis, U., & Classen-Houben, D. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.005 · Cited by 31
Joseph, J. J., Wang, X., Roux, A. V. D., Sánchez, B. N., Seeman, T. E., Needham, B. L., & Golden, S. H. (2016) · Metabolism · doi:10.1016/j.metabol.2016.12.001 · Cited by 31
Lumbar epidural lipomatosis is associated with visceral fat and metabolic disorders
Morishita, S., Arai, Y., Yoshii, T., Sakai, K., Hirai, T., & Okawa, A. (2018) · European Spine Journal · doi:10.1007/s00586-018-5584-2 · Cited by 31
Fotsch, C. H., Bartberger, M. D., Bercot, E. A., Chen, M., Cupples, R. L., Emery, M., Fretland, J., Guram, A. S., Hale, C., Han, N., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801073z · Cited by 31
Local Glucocorticoid Activation by 11β-Hydroxysteroid Dehydrogenase 1 in Keratinocytes
Terao, M., Itoi, S., Matsumura, S., Yang, L., Murota, H., & Katayama, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.014 · Cited by 31
McEwen, B. S., & Chattarji, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-30405-2_14 · Cited by 31
Glucocorticoids and Insulin Sensitivity: Dissociation of Insulin’s Metabolic and Vascular Actions
Perry, C. G., Spiers, A., Cleland, S. J., Lowe, G. D. O., Petrie, J. R., & Connell, J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021605 · Cited by 31
“This hypothesis is supported by genetic studies of mice with altered expression of the 11 -hydroxysteroid dehydrogenase type 1 enzyme (39, 40).”
MethodInsulin sensitisation in the treatment of Type 2 diabetes
Tadayyon, M., & Smith, S. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.307 · Cited by 31
“In man, 11β-HSD-1 is highly expressed in both the liver and adipose tissue [90].”
BackgroundEdgerton, D. S., Basu, R., Ramnanan, C. J., Farmer, T. D., Neal, D. W., Scott, M. F., Jacobson, P. B., Rizza, R. A., & Cherrington, A. D. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00740.2009 · Cited by 30
“Whereas mice overexpressing 11 -HSD1 developed visceral obesity and hyperlipidemia (24, 31), knockout or inhibition of the enzyme reduced fasting plasma triglycerides, NEFA, and cholesterol and prevented progression of atherosclerosis in mice (1, 16, 27).”
BackgroundObesity, Metabolic Syndrome and Disorders of Energy Balance
Han, J. C., & Weiss, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00024-5 · Cited by 30
Sun, X., Feng, M., Lü, L., Zhao, Z., Bao, X., Deng, K., Yao, Y., Zhu, H., & Wang, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.600323 · Cited by 30
“Transgenic mice models expressing increased 11bHSD-1 activity selectively in either adipose tissue or liver would develop visceral obesity or hepatic steatosis respectively, and both exhibited visceral obesity and the metabolic syndrome, such as insulin-resistance, hyperlipidemia and hypertension (17, 18), which sugge…”
BackgroundChen, Y., Xu, D., Xia, X., Chen, G., Xiao, H., Chen, L., & Wang, H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105942 · Cited by 30
Czegle, I., Csala, M., Mandl, J., Benedetti, A., Karádi, I., & Bánhegyi, G. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i4.129 · Cited by 30
Tsugita, M., Iwasaki, Y., Nishiyama, M., Taguchi, T., Shinahara, M., Taniguchi, Y., Kambayashi, M., Terada, Y., & Hashimoto, K. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.07.005 · Cited by 30
Lee, J. H., Gao, Z., & Ye, J. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00029.2013 · Cited by 30
Burén, J., Bergström, S.-A., Loh, E., Söderström, I., Olsson, T., & Mattsson, C. (2007) · Endocrinology · doi:10.1210/en.2006-0897 · Cited by 26
Taira, S.-I., Shimabukuro, M., Higa, M., Yabiku, K., Kozuka, C., Ueda, R., Sunagawa, S., Ohshiro, Y., Doi, M., Nanba, T., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0521 · Cited by 30
“In addition to visceral fat accumulation (1, 2), ectopic lipid deposition, especially in the liver and skeletal muscle, has been implicated in the pathophysiology of diabetes, insulin resistance and dyslipidemia (3).”
BackgroundMethodSelf-citationLoerz, C., & Maser, E. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.030 · Cited by 30
Mouse models of peripheral metabolic disease
Xavier, G. D. S., & Hodson, D. J. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.009 · Cited by 30
Sun, S., Hanzawa, F., Umeki, M., Ikeda, S., Mochizuki, S., & Oda, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201261 · Cited by 30
Dammann, C., Stapelfeld, C., & Maser, E. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.02.018 · Cited by 30
Cardiometabolic Syndrome: An Update on Available Mouse Models
Aravani, D., Kassi, E. N., Chatzigeorgiou, A., & Vakrou, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721388 · Cited by 30
Ito‐Kobayashi, M., Aoyagi, A., Tanaka, I., Muramatsu, Y., Umetani, M., & Takatsu, T. (2008) · The Journal of Antibiotics · doi:10.1038/ja.2008.121 · Cited by 30
“As glucocorticoids oppose the insulin effect, several studies with mice lacking [6] or overexpressing [7] 11b -HSD1 reported that 11b-HSD1 plays an important role in Type 2 diabetes and metabolic syndrome.”
BackgroundMetabolic syndrome is a low-grade systemic inflammatory condition
Das, U. N. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.19 · Cited by 30
Pyridine amides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1
Wang, H., Ruan, Z., Li, J. J., Simpkins, L. M., Smirk, R. A., Wu, S. C., Hutchins, R. D., Nirschl, D. S., Kirk, K. V., Cooper, C. B., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.069 · Cited by 30
Morita, H., Isomura, Y., Mune, T., Daido, H., Takami, R., Yamakita, N., Ishizuka, T., Takeda, N., Yasuda, K., & Gómez-Sánchez, C. E. (2003) · Metabolism · doi:10.1016/j.metabol.2003.06.005 · Cited by 30
Symonds, M. E., Gopalakrishnan, G. S., Bispham, J., Pearce, S., Dandrea, J., Mostyn, A., Ramsay, M., & Stephenson, T. J. (2003) · Archives of Physiology and Biochemistry · doi:10.1076/apab.111.1.45.15141 · Cited by 30
“Adaptations in adipose tissue deposition and metabolism following over expression of 11b-HSD type 1 do not occur in isolation but are accompanied by pronounced insulin-resistant diabetes, hyperlipidemia and hyperphagia, despite hyperleptinemia (Masuzaki et al., 2001).”
BackgroundInfluentialElucidating cis- and trans-regulatory variation using genetical genomics
SLADEK, R. M., & Hudson, T. J. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.001 · Cited by 30
“transcript, Hsd11b1, were previously shown to have reduced OFPM [ 32 ].”
BackgroundŠimonytė, K., Rask, E., Näslund, I., Angelhed, J., Lönn, L., Olsson, T., & Mattsson, C. (2009) · Obesity · doi:10.1038/oby.2009.99 · Cited by 29
“This finding supports the hypothesis that increased fat accumulation is accompanied by reduced adiponectin levels (13,33).”
BackgroundResultTsai, S., Hung, H., Shih, M. M., Chang, F., Chung, B., Wang, C., Lin, Y., & Kuo, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202101570r · Cited by 29
Barrea, L., Verde, L., Camajani, E., Šojat, A. S., Marina, L., Savastano, S., Colao, A., Caprio, M., & Muscogiuri, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02068-6 · Cited by 30
“In animal models, mice-overexpressing adipocyte 11β HSD-1 developed all cortisol-related comorbidities such as diabetes, hypertension, and visceral obesity [21].”
BackgroundWang, Y., Nakagawa, Y., Liu, L., Wang, W., Ren, X., Anghel, A., Lutfy, K., Friedman, T. C., & Liu, Y. (2010) · Diabetologia · doi:10.1007/s00125-010-1956-9 · Cited by 29
“Indeed, enhanced 11β-HSD1 could result in the production of excess tissue GCs and induction of GC-receptor-mediated local GC action related to glucose homeostasis, insulin action and adiposity, all of which are associated with the development of type 2 diabetes and visceral obesity [16–18].”
The Role of 11ß-Hydroxysteroid Dehydrogenase 1 in Adipogenesis in Thyroid-Associated Ophthalmopathy
Tomlinson, J., Durrani, O. M., Bujalska, I. J., Gathercole, L., Tomlins, P. J., Reuser, T. T. Q., Rose, G. E., Curnow, J., Stewart, P. M., Walker, E. A., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0873 · Cited by 29
Lepifre, F., Christmann‐Franck, S., Roche, D., Leriche, C., Carniato, D., Charon, C., Hallakou‐Bozec, S., Doaré, L., Schmidlin, F., Lecomte, M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.123 · Cited by 29
Kansuinone, a novel euphane-type triterpene from Euphorbia kansui
Guo, J. Q., He, H., Fang, X., Di, Y., Li, S., Zhang, Z., Leng, Y., Hua, H., & Hao, X. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.09.099 · Cited by 29
Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy
Wang, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_6 · Cited by 29
“Transgenic mice were created with selective overexpression of 11b-HSD1 in adipose tissue at a level similar to that observed in human obesity (Masuzaki et al. 2001).”
BackgroundInfluentialPathogenesis and treatment of HIV lipohypertrophy
Leung, V., & Glesby, M. J. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283420eef · Cited by 29
Ketoconazole, an Antifungal Agent, Protects Against Adiposity Induced by a Cafeteria Diet
Campión, J., & Martínez, J. A. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-825729 · Cited by 29
Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
Tice, C. M., Zhao, W. L., Xu, Z., Cacatian, S. T., Simpson, R. D., Ye, Y.-J., Singh, S. B., McKeever, B. M., Lindblom, P., Guo, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.082 · Cited by 29
Differential Modulation of 3T3-L1 Adipogenesis Mediated by 11β-Hydroxysteroid Dehydrogenase-1 Levels
Kim, J., Temple, K. A., Jones, S. A., Meredith, K. N., Basko, J. L., & Brady, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606197200 · Cited by 29
Phytoestrogens as inhibitors of fungal 17β-hydroxysteroid dehydrogenase
Kristan, K., Krajnc, K., Konc, J., Gobec, S., Stojan, J., & Rižner, T. L. (2005) · Steroids · doi:10.1016/j.steroids.2005.02.023 · Cited by 29
Metadata
- Authors
- Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University of Edinburgh (GB)
- Corresponding author
- Flier, Jeffrey S.
- Venue
- Science
- Published
- 2001-12-07
- Volume
- 294
- Issue
- 5549
- Pages
- 2166-2170
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2117268230
- Cited by
- 1,766
- References
- 34
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 30 · 2023: 19 · 2022: 23 · 2021: 44 · 2020: 34 · 2019: 39 · 2018: 54 · 2017: 52 · 2016: 63 · 2015: 74 · 2014: 72 · 2013: 106 · 2012: 98
- FWCI
- 71.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- visceral obesity, metabolic syndrome, 11β-hydroxysteroid dehydrogenase type 1, glucocorticoids, corticosterone, adipose tissue, transgenic mice, insulin resistance, diabetes mellitus, hyperlipidemia, hyperphagia, leptin, high-fat diet
- MeSH terms
- Abdomen, Adipose Tissue, Animals, Body Composition, Corticosterone, Dietary Fats, Disease Models, Animal, Eating, Humans, Hydroxysteroid Dehydrogenases, Hyperglycemia, Hyperinsulinism, Insulin Resistance, Lipids, Lipoprotein Lipase, Male, Mice, Transgenic, Obesity, Receptors, Glucocorticoid, Viscera, Weight Gain, Adipocytes, Gene Targeting, Leptin, Metabolic Syndrome, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Cell Size, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.